We showed that systemic expression of HGF via AAV-HGF treatment failed to promote resistance to BRAF inhibition in G361 tumor xenografts, whereas local/tumor doxycycline–induced expression of HGF was capable of conferring resistance. The gene discussed is BRAF; the disease is neoplasm.